Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
复制标题
非酒精性脂肪肝作为人类代谢疾病：文献综述。
DOI：
10.1111/dom.14322
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Sanyal AJ
中科院分区：
文献类型：
--
作者：
Cariou B;Byrne CD;Loomba R;Sanyal AJ
进行系统性文献综述，以确定最近的流行病学，生物标志物，遗传和临床证据，扩大我们对非酒精性脂肪肝（NAFLD）作为一种代谢紊乱的理解。我们使用PubMed进行了文献检索，以识别过去5年中发表的试验、观察性研究和Meta分析。共有95篇文献符合预先规定的纳入标准，并报告了NAFLD/非酒精性脂肪性肝炎（NASH）与代谢功能障碍之间的相互作用，包括疾病负担和/或流行病学（n = 10）、病理生理学、风险因素和相关疾病（n = 29）、诊断和生物标志物（n = 34）以及治疗方法（n = 22）。越来越多的证据表明，NAFLD/NASH发病机制与代谢功能障碍机制之间存在联系，通过肝脏脂质蓄积、胰岛素抵抗、炎症、细胞凋亡和肝脏内的纤维化重塑。非酒精性脂肪肝与肥胖、代谢综合征和2型糖尿病频繁共存支持了这一前提。最初设想用于2型糖尿病或肥胖症的治疗方法（如胰高血糖素样肽-1受体激动剂、钠-葡萄糖共转运蛋白-2抑制剂、胰岛素增敏剂和减肥手术）已显示出对NAFLD/NASH患者有益的有希望的迹象。鉴于NAFLD和代谢功能障碍之间的复杂相互作用，迫切需要多学科合作和建立NAFLD患者的护理方案，这些方案是个性化的，理想地支持降低总体代谢风险以及NASH治疗。
To conduct a systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of nonalcoholic fatty liver disease (NAFLD) as a metabolic disorder. We performed a literature search using PubMed to identify trials, observational studies and meta‐analyses published in the past 5 years. A total of 95 publications met prespecified inclusion criteria and reported on the interplay between NAFLD/nonalcoholic steatohepatitis (NASH) and metabolic dysfunction, in terms of disease burden and/or epidemiology (n = 10), pathophysiology, risk factors and associated conditions (n = 29), diagnosis and biomarkers (n = 34), and treatment approaches (n = 22). There is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction, through liver lipid accumulation, insulin resistance, inflammation, apoptosis, and fibrogenic remodelling within the liver. The frequent co‐occurrence of NAFLD with obesity, metabolic syndrome and type 2 diabetes supports this premise. Therapeutic approaches originally envisaged for type 2 diabetes or obesity (such as glucagon‐like peptide‐1 receptor agonists, sodium‐glucose co‐transporter‐2 inhibitors, insulin sensitizers and bariatric surgery) have shown promising signs of benefit for patients with NAFLD/NASH. Given the complex interplay between NAFLD and metabolic dysfunction, there is an urgent need for multidisciplinary collaboration and established protocols for care of patients with NAFLD that are individualized and ideally support reduction of overall metabolic risk as well as treatment for NASH.
登录
查看更多内容
影响因子：
13.5
作者：
Csak, Timea;Ganz, Michal;Pespisa, Justin;Kodys, Karen;Dolganiuc, Angela;Szabo, Gyongyi
通讯作者：
Szabo, Gyongyi
影响因子：
168.9
作者：
Ambery, Philip;Parker, Victoria E.;Jermutus, Lutz
通讯作者：
Jermutus, Lutz
影响因子：
13.5
作者：
Bechmann, Lars P.;Kocabayoglu, Peri;Canbay, Ali
通讯作者：
Canbay, Ali
影响因子：
15.9
作者：
Caussy, Cyrielle;Soni, Meera;Loomba, Rohit
通讯作者：
Loomba, Rohit
DOI：
10.1080/17474124.2019.1580143
发表时间：
2019-04-03
影响因子：
3.9
作者：
Chen, Jin;Bian, Dongxue;Shi, Junping
通讯作者：
Shi, Junping